(S)-2,6-Bis-methoxycarbonylamino-hexanoic acid | 113694-60-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2,6-Bis-methoxycarbonylamino-hexanoic acid
• 英文别名: Dicarbomethoxy-L-lysine；(2S)-2,6-bis(methoxycarbonylamino)hexanoic acid
• CAS: 113694-60-3
• 化学式: C₁₀H₁₈N₂O₆
• 分子量: 262.263
• InChiKey: UUONLAKZGBJOET-ZETCQYMHSA-N

物化性质

• 沸点：
  485.7±40.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-2,6-Bis-methoxycarbonylamino-hexanoic acid 在 盐酸 、 tetrabutylammonium tetrafluoroborate 作用下， 生成 methyl (2S)-6-methoxy-2,6-bis(methoxycarbonylamino)hexanoate
  参考文献：
  名称：

  Ludwig, Catarina; Wistrand, Lars-G., Acta Chemica Scandinavica, 1994, vol. 48, # 4, p. 367 - 371

  摘要：

  DOI：
• 作为产物：
  描述：

  L-赖氨酸 、 氯甲酸甲酯 在 sodium hydroxide 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 (S)-2,6-Bis-methoxycarbonylamino-hexanoic acid
  参考文献：
  名称：

  Ludwig, Catarina; Wistrand, Lars-G., Acta Chemica Scandinavica, 1994, vol. 48, # 4, p. 367 - 371

  摘要：

  DOI：

文献信息

• [EN] NOVEL BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：ENANTA PHARM INC

  公开号：WO2013052369A1

  公开（公告）日：2013-04-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐、酯或前药：其抑制RNA含量的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者注射包含本发明化合物的制药组合物来治疗HCV感染的方法。
• NOVEL PEGYLATED AMINO ACID DERIVATIVES AND THE PROCESS TO SYNTHESIZE THE SAME
  申请人：NIEMCZYK HENRY JOSEPH

  公开号：US20080234497A1

  公开（公告）日：2008-09-25

  The present invention is a series of novel pegylated amino acid derivatives containing branched polyethylene glycols, which are either the same or different molecular weights. Additionally, the N-pegylated lysine derivatives are enantiomerically pure. Also disclosed are oligopeptides such as Lysine-Lysine in which the free amino groups are protected as pegylated carbamates. 9-BBN complexes of lysine in which the epsilon nitrogen is functionalized as a pegylated carbamate and Bis pegylated derivatives of multifunctional heteroatom-containing amino acids such as cysteine, serine and glutamic acid are also disclosed. The present invention is also the process to prepare the novel pegylated amino acid derivatives for subsequent reaction with proteins. The process for synthesizing N-pegylated lysine derivatives in which the 9-borabicyclononane (9-BBN) complex of lysine is functionalized as a pegylated carbamate. The process in which the epsilon nitrogen of 9-BBN complex of lysine, which contains a pegylated polymer at the epsilon nitrogen, is hydrolyzed with aqueous hydrochloric acid and a process for synthesizing activated esters of N-pegylated amino acids by esterification of an N-pegylated amino acid are disclosed. A process in which N-epsilon pegylated lysine is reacted with an active pegylated ester is also disclosed. The novel pegylated amino acid derivatives are new chemical entities (NCE's) not previously described. The processes to prepare these novel pegylated amino acid derivatives have also not previously been described.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20
• US8101729B2
  申请人：——

  公开号：US8101729B2

  公开（公告）日：2012-01-24
• US9765087B2
  申请人：——

  公开号：US9765087B2

  公开（公告）日：2017-09-19